Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-06-25
2008-09-09
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C546S196000, C546S209000, C546S210000, C546S211000, C546S212000
Reexamination Certificate
active
07423052
ABSTRACT:
A invention relates to N aroyl cyclic amine derivatives and their use as pharmaceuticals, specifically as orexin receptor antagonists.
REFERENCES:
patent: 5547978 (1996-08-01), Christensen et al.
patent: 6150356 (2000-11-01), Lloyd et al.
patent: 6235755 (2001-05-01), El Tayer et al.
patent: 6326379 (2001-12-01), Macor et al.
patent: 6410529 (2002-06-01), Chan et al.
patent: 6423723 (2002-07-01), El Tayer et al.
patent: 6511977 (2003-01-01), Lloyd et al.
patent: 6596730 (2003-07-01), Coulton et al.
patent: 6638980 (2003-10-01), Su et al.
patent: 6649656 (2003-11-01), Tsuchiya et al.
patent: 6653338 (2003-11-01), El Tayer et al.
patent: 6677354 (2004-01-01), Branch et al.
patent: 6706720 (2004-03-01), Atwal et al.
patent: 6784189 (2004-08-01), Lloyd et al.
patent: 6881753 (2005-04-01), Lloyd et al.
patent: 6890932 (2005-05-01), Tsuchiya et al.
patent: 6943160 (2005-09-01), Branch et al.
patent: 6967196 (2005-11-01), Smith et al.
patent: 7157451 (2007-01-01), Atwal et al.
patent: 2004/0143115 (2004-07-01), Branch et al.
patent: 2004/0180887 (2004-09-01), Branch et al.
patent: 2004/0192673 (2004-09-01), Gaillard et al.
patent: 2004/0215014 (2004-10-01), Chan et al.
patent: 2006/0040937 (2006-02-01), Branch et al.
patent: 1 162 196 (2001-12-01), None
patent: WO 99/58533 (1999-11-01), None
patent: WO 00/37458 (2000-06-01), None
patent: WO 00/47576 (2000-08-01), None
patent: WO 01/44228 (2001-06-01), None
Smart et al., “Orexins and the treatment of obesity,” European Journal of Pharmacology 440 (2002) 199-212.
Lang et al., “Structure-Activity Studies, etc.,” J. Med. Chem. 2004, 47, 1153-1160.
Kilduff et al., “The hypocretin/orexin, etc.,” Trends Neurosi. 2000, 23, 359-365.
Taheri et al., “The Role of Hyrpocretins,etc.,” Annu. Rev. Neurosci., 2002, 25:283-313.
Cai et al., “Antagonists of the orexin receptors”, Expert Opin. Ther. Patents (2006) 16(5), 631-646.
Rubini et al., “Synthesis of , etc.,” Tetrahedron 42 (21), 6039-6045, 1986.
Patani et al., “Bioisoterism: A Rational, etc.,” Chem. Rev. 1996, 96, 3147-3148 and 3170.
Marshall, et al., “Absolute Configuration of alpha-Methyldopamine Formed Metabolically from alpha-Methyldopa in Man.”J. Med. Chem., 16(3): 266-270 (1973).
Langmead et al. Br. J. Pharmacol., 141: 340-346 (2004).
Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).
Duxon et al. Psychopharmacology, 153: 203-209 (2001).
White et al. Peptides, 26: 2331-2338 (2005).
Ishii et al. Behav. Brain Res., 160: 11-24 (2005).
Ishii et al. Behav. Brain Res., 157: 331-341 (2005).
Ishii et al. Physiol. & Behav., 81: 129-140 (2004).
Smith et al. Neurosci. Lett., 341: 256-258 (2003).
Haynes et al. Regulatory Peptides, 104: 153-159 (2002).
Bingham et al. Pain, 92: 81-90 (2001).
Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).
Smart et al. Br. J. Pharmacol., 132: 1179-1182 (2001).
Jones et al. Psychopharmacology, 153: 210-218 (2001).
Haynes et al. Regulatory Peptides, 96: 45-51 (2000).
Boutrel et al.PNAS, 102(52): 19168-19173 (2005).
Borgland et al.Neuron, 49: 589-601 (2006).
Harris et al.Nature, 437: 556-559 (2005).
Brisbare-Roch et al.Nature Medicine, 13(2): 150-155 (2007).
Hagan et al.Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).
Piper et al.Eur. J. Neurosci., 12: 726-730 (2000).
Patani et al.Chem. Rev., 96: 3147-3176 (1996).
Office Action, U.S. Appl. No. 10/481,133, filed Apr. 26, 2004.
King. Bioisoteres, Conformational etc., Med. Chem. Principle and Practice (1994) 206-209.
Rogers et al.Neuropeptides, 36(5): 303-325 (2002).
Mori et al.Chem. Pharm. Bull., 32(10): 3840-47 (1984).
Defoin et al.,Helv. Chim. Acta, 75(1): 109-123 (1992).
Baker et al.Chem. Abstract, 52: 2194 (1958).
Shaw et al.Chem. Abstracts, 90: 137628 (1979).
Ehrhardt et al.Chem. Abstracts, 109: 149536 (1988).
Collins et al.J. Med. Chem., 41(12): 5037-5054 (1998).
Sohda et al.Chem.&Pharm. Bull., Pharm. Soc. of Japan, 30(10): 3580-3600 (1982).
Dieter et al.J. Am. Chem. Soc., 109(7): 2040-2046 (1987).
Bal et al.Polish J. Chem., Polish Chem. Soc., 55: 1681-1684 (1981).
Bal et al.Polish J. Chem., Polish Chem. Soc., 55(10): 2171-2175 (1981).
Wanner et al.Arch. Pharm., 326(10): 799-802 (1993).
Suzuki et al.Heterocycles, 50(1): 89-94 (1999).
Database Crossfire Beilstein ′Online! Database Accession No. 4519278 (BRN), XP002211820 & Tetrahedron Lett., 28(17): 1949-1952 (1987).
Database Crossfire Beilstein ′Online! Database Accession No. 7095929 (BRN), XP002211821 & J. Chem. Soc. Perkin 1, (10):2477-2486 (1982).
Database Crossfire Beilstein ′Online! Database Accession No. 339072 (BRN), XP002211822 & Rocz. Chem, 29: 1029-1039 (1955).
Database Crossfire Beilstein ′Online! Database Accession No. 1491413 (BRN), XP002211823 & Chem. Pharm. Bull, 16(10): 2074-2077 (1968).
Database Crossfire Beilstein ′Online! Database Accession No. 1600999 (BRN), XP002211824 & J. Org. Chem, 29: 2860 (1964).
Johns et al.Chem. Abstracts, 133: 177112 (2000).
Chan Wai Ngor
Johns Amanda
Johnson Christopher Norbert
Novelli Riccardo
Porter Roderick Alan
Kinzig Charles M.
McCarthy Mary E.
Morris Patricia L
Sieburth Kathryn L.
SmithKline Beecham p.l.c.
LandOfFree
Piperidine compounds for use as orexin receptor antagoinst does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine compounds for use as orexin receptor antagoinst, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine compounds for use as orexin receptor antagoinst will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988748